Pharmacotherapy of chronic hepatitis C virus infection – the IDEAL trial: ‘2b or not 2b (= 2a), that is the question’

Bibliography

• Hoofnagle JH, Mullen KD, Jones DB, Treatment of chronic non-A, non-B. hepatitis with recombinant human alpha interferon: A preliminary report.N Engl J Med 1986;315:1575-8
   Google Scholar
• Marcellin P, Boyer N, Gervais A, Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997;127:875-81
   PubMed Web of Science ®Google Scholar
• Shiffman ML, Hofmann CM, Thompson EB, Relationship between biochemical, virological. and histological response during interferon treatment of chronic hepatitis C. Hepatology 1997;26:780-5
   Google Scholar
• Shiratori Y, Imazeki F, Moriyama M, Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000;132:517-24
   PubMed Web of Science ®Google Scholar
• Poynard T, McHutchison J, Davis GL, Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000;32:1131-7
   PubMed Web of Science ®Google Scholar
• Camma C, Di Bona D, Schepis F, Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology 2004;39:333-42
   PubMed Web of Science ®Google Scholar
• Poynard T, McHutchison J, Manns M, Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122:1303-13
   PubMed Web of Science ®Google Scholar
• Poynard T, Ratziu V, McHutchison J, Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003;38:75-85
   PubMed Web of Science ®Google Scholar
• Nishiguchi S, Kuroki T, Nakatani S, Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051-5
   PubMed Web of Science ®Google Scholar
• Mazzelia G, Accogli E, Sottili S, Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996;24:141-7
   PubMedGoogle Scholar
• Imai Y, Kawata S, Tamura S, Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Ann Intern Med 1998;129:94-9
   PubMed Web of Science ®Google Scholar
• Kasahara A, Hayashi N, Mochizuki K, Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 1998;27:1394-402
   PubMed Web of Science ®Google Scholar
• Yoshida H, Shiratori Y, Moriyama M, Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999;131:174-81
   PubMed Web of Science ®Google Scholar
• Ikeda K, Saitoh S, Arase Y, Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999;29:1124-30
   PubMed Web of Science ®Google Scholar
• Okanoue T, Itoh Y, Minami M, Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. J Hepatol 1999;30:653-9
   PubMed Web of Science ®Google Scholar
• Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management. and treatment of hepatitis C: an update Hepatology 2009;49:1335-74
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Sette H Jr, Morgan TR, Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:370-81
   PubMedGoogle Scholar
• Yu M-L, Dai C-Y, Lin Z-Y, A randomized trial of 24- vs. 48-week course of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan. Liver Int 2006;26:73-81
   PubMed Web of Science ®Google Scholar
• Brandao C, Barone A, Carrilho F, The results of a randomized trial looking at 24 weeks vs 48 weeks of treatment with peginterferon alpha-2a (40 kDa) and ribavirin combination therapy in patients with chronic hepatitis C genotype 1. J Viral Hepat 2006;13:552-9
   PubMedGoogle Scholar
• Yu M-L, Dai C-Y, Huang J-F, Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008;47:1884-93
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Hultcrantz R, Bourliere M, Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients with HCV genotypes 2 or 3. J Hepatol 2004;40:993-9
   PubMed Web of Science ®Google Scholar
• Berg T, von Wagner M, Nasser S, Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006;130:1086-97
   PubMed Web of Science ®Google Scholar
• Sanchez-Tapias JM, Diago M, Escartin P, Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006;131:451-60
   PubMed Web of Science ®Google Scholar
• Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders. Hepatology 2007;46:1688-94
   PubMed Web of Science ®Google Scholar
• Dalgard O, Bjoro K, Hellum KB, Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004;40:1260-5
   PubMed Web of Science ®Google Scholar
• Mangia A, Santoro R, Minerva N, Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005;352:2609-17
   PubMed Web of Science ®Google Scholar
• von Wagner M, Huber M, Berg T, Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005;129:522-7
   PubMed Web of Science ®Google Scholar
• Yu M-L, Dai C-Y, Huang J-F, A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007;56:553-9
   PubMed Web of Science ®Google Scholar
• Shiffman ML, Suter F, Bacon BR, Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007;357:124-34
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Manns M, Patel K, Adherence to combination therapy enhanced sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002;123:1061-9
   PubMed Web of Science ®Google Scholar
• Bronowicki J-P, Ouzan D, Asselah T, Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology 2006;131:1040-8
   PubMed Web of Science ®Google Scholar
• Shiffman ML, Ghany MG, Morgan TR, Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 2007;132:103-12
   PubMed Web of Science ®Google Scholar
• Reddy KR, Shiffman ML, Morgan TR, Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alpfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol 2007;5:124-9
   PubMed Web of Science ®Google Scholar
• Saracco G, Rosina F, Torrani-Cerenzia MR, A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis. J Hepatol 1990;11:S43-9
   PubMedGoogle Scholar
• Gomez-Rubio M, Porres JC, Castillo I, Prolonged treatment (18 months) of chronic hepatitis C with recombinant alpha-interferon in comparison with a control group. J Hepatol 1990;11:S63-7
   PubMedGoogle Scholar
• Causse X, Goginot H, Chevallier M, Comparizon of 1 or 3 MU interferon alpha-2b and placebo in patients with chronic non-A. non-B hepatitis. Gastroenterology 1991;101:497-502
   Google Scholar
• Alberti A, Chemello L, Bonetti P, Treatment with interferon(s) of community-acquired chronic hepatitis and cirrhosis type C. J Hepatol 1993;17:S123-6
   PubMedGoogle Scholar
• Caporaso N, Suozzo R, Morisco F, Recombinant human interferon alfa-2a therapy of chronic hepatitis C with or without cirrhosis: comparison of 3 or 6 MU for 1 year. Ital J Gastroenterol 1993;25:482-6
   PubMedGoogle Scholar
• Negro F, Baldi M, Mondardini A, Continuous versus intermittent therapy for chronic hepatitis C with recombinant interferon alfa-2a. Gastroenterology 1994;107:479-85
   PubMedGoogle Scholar
• Diodati G, Bonetti P, Noventa F, Treatment of chronic hepatitis C with recombinant human interferon-alfa 2a: results of a randomized controlled clinical trial. Hepatology 1994;19:1-5
   PubMed Web of Science ®Google Scholar
• Reichard O, Foberg U, Fryden A, High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon alpha-2b for 60 weeks. Hepatology 1994;19:280-5
   PubMed Web of Science ®Google Scholar
• Castillo I, Bartolome J, Navas S, Virological and biochemical long-term follow-up of patients with chronic hepatitis C treated with interferon. Hepatology 1994;19:1342-6
   PubMedGoogle Scholar
• Poynard T, Bedossa P, Chevallier M, A comparison of three interferon alpha-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995;332:1457-62
   PubMed Web of Science ®Google Scholar
• Marcellin P, Pouteau M, Martinot-Peignoux M, Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C. Gastroenterology 1995;109:156-65
   PubMedGoogle Scholar
• Kasahara A, Hayashi N, Hiramatsu N, Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. Hepatology 1995;21:291-7
   PubMed Web of Science ®Google Scholar
• Chemello L, Bonetti P, Cavalletto L, Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology 1995;22:700-6
   PubMed Web of Science ®Google Scholar
• Yokosuka O, Kato N, Ito Y, Efficacy of longterm interferon treatment in chronic liver disease evaluated by sensitive polymerase chain reaction assay for hepatitis C virus RNA. Gut 1995;37:721-6
   PubMedGoogle Scholar
• Lin R, Roach E, Zimmerman M, Interferon alpha-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rate. Results of the first multicentre Australian trial. J Hepatol 1995;23:487-96
   PubMed Web of Science ®Google Scholar
• Hakozaki Y, Shirahama T, Katou M, A controlled study to determine the optimal dosage regimen of interferon-alpha 2b in chronic hepatitis C. Am J Gastroenterol 1995;90:1246-9
   PubMedGoogle Scholar
• Shiffman ML, Hofmann CM, Luketic VA, Improved sustained response following treatment of chronic hepatitis C by gradual reduction in the interferon dose. Hepatology 1996;24:21-6
   PubMedGoogle Scholar
• Poynard T, Leroy V, Cohard M, Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effect of dose and duration. Hepatology 1996;24:778-89
   PubMed Web of Science ®Google Scholar
• Lindsay KL, Davis GL, Schiff ER, Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatology 1994;24:1034-40
   Google Scholar
• Rumi M, Del Ninno E, Parravicini MLK, A prospective, randomized trial comparing lymphoblastoid to recombinant interferon alfa 2a as therapy for chronic hepatitis C. Hepatology 1996;24:1366-70
   PubMed Web of Science ®Google Scholar
• Tassopoulos NC, Karvountzis G, Touloumi G, Comparative efficacy of a high or low dose of interferon alpha 2b in chronic hepatitis C: a randomized controlled trial. Am J Gastroenterol 1996;91:1734-8
   PubMedGoogle Scholar
• Carithers RL Jr, Emerson SS. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology 1997:26;S83-8
   PubMed Web of Science ®Google Scholar
• Lee WM. Therapy of hepatitis C: interferon alfa-2a trials. Hepatology 1997;26:S89-95
   Google Scholar
• McHutchison JG, Gordon SC, Schiff ER, Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-92
   PubMed Web of Science ®Google Scholar
• Poynard T, Marcellin P, Lee SS, Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-32
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Feinman SV, Rasenack J, Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-72
   PubMed Web of Science ®Google Scholar
• Lindsay KL, Trepo C, Heintges T, A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403
   PubMed Web of Science ®Google Scholar
• Lai M-Y, Kao J-H, Yang P-M, Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996;111:1307-12
   PubMed Web of Science ®Google Scholar
• Davis GL, Esteban-Mur R, Rustgi VK, Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998;339:1493-9
   PubMed Web of Science ®Google Scholar
• Brillanti S, Garson J, Foli M, A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa- resistant chronic hepatitis C. Gastroenterology 1994;107:812-7
   PubMed Web of Science ®Google Scholar
• Bell H, Hellum K, Harthug S, Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. Scand J Gastroenterol 1999;34:194-8
   PubMedGoogle Scholar
• Shiffman ML, Hofmann CM, Gabbay J, Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. Am J Gastroenterol 2000;95:2928-35
   PubMedGoogle Scholar
• Delgado C, Francis GE, Fisher D. The uses and properties of PEG-linked proteins. Crit Rev Ther Drug Carrier Syst 1992;9:249-304
   PubMed Web of Science ®Google Scholar
• Inada Y, Furukawa M, Sasaki H, Biomedical and biotechnological applications of PEG- and PM-modified proteins. Trends Biotech 1995;13:86-91
   PubMed Web of Science ®Google Scholar
• Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 2001;40:539-51
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Feinman SV, Rasenack J, Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-72
   PubMed Web of Science ®Google Scholar
• Heathcote EJ, Shiffman ML, Cooksley WGE, Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343:1673-80
   PubMed Web of Science ®Google Scholar
• Reddy KR, Wright TL, Pockros PJ, Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001;33:433-8
   PubMed Web of Science ®Google Scholar
• Lindsay KL, Trepo C, Heintges T, A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403
   PubMed Web of Science ®Google Scholar
• Pockros PJ, Carithers R, Desmond P, Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter. randomized controlled trial Am J Gastroenterol 2004;99:1298-305
   PubMed Web of Science ®Google Scholar
• Foster GR. Pegylated interferons: chemical and clinical differences. J Viral Hepat 2004;20:825-30
   Google Scholar
• Zeuzem S, Welsch C, Herrmann E. Pharmacokinetics of peginterferons. Semin Liver Dis 2003;23:S23-8
   PubMed Web of Science ®Google Scholar
• Reddy KR. Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD). Semin Liver Dis 2004;24:S33-8
   PubMed Web of Science ®Google Scholar
• Grace MJ, Cutler DL, Bordens RW. Pegylated IFNs for chronic hepatitis C: an update. Expert Opin Drug Deliv 2005;2:219-26
   PubMedGoogle Scholar
• Caliceti P. Pharmacokinetics of pegylated interferons: what is misleading? Dig Liver Dis 2004;36:S333-8
   PubMedGoogle Scholar
• Bruno R, Sacchi P, Scagnolari C, Pharmacodynamics of peginterferon alfa-2a and peginterferon alfa-2b in interferon-naïve patients with chronic hepatitis C: a randomized, controlled study. Aliment Pharmacol Ther 2007;26:369-76
   PubMed Web of Science ®Google Scholar
• Pegasys product label. USA: Roche, 2005. Available from: http://www.rocheusa.com/products/pegasys/pi.pdf.
   Google Scholar
• PEG-Intron product label. Schering Plough, 2005. Available from: http://www.spfiles.com/pipeg-intron.pdf.
   Google Scholar
• Manns MP, McHutchison JG, Gordon SC, Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65
   PubMed Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy KR, Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;345:975-82
   Google Scholar
• Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351:438-50
   PubMed Web of Science ®Google Scholar
• Chung RT, Andersen J, Volberding P, Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004;351:451-9
   PubMed Web of Science ®Google Scholar
• Bruno S, Camma C, Di Marco V, Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial. J Hepatol 2004;41:474-81
   PubMed Web of Science ®Google Scholar
• Glue P, Rouzier-Panis R, Raffanel C, A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. Hepatology 2000;32:647-53
   PubMed Web of Science ®Google Scholar
• Ferenci P, Fried MW, Shiffman ML, Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005;43:425-33
   PubMed Web of Science ®Google Scholar
• Kuboki M, Iino S, Okuno T, Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients. J Gastroenterol Hepatol 2007;22:645-52
   PubMedGoogle Scholar
• Davis GL, Wong JB, McHutchison JG, Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38:645-52
   PubMed Web of Science ®Google Scholar
• Shiffman ML, Di Bisceglie AM, Lindsay KL, Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004;126:1015-23
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Diago M, Gane E, Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004;127:1724-32
   PubMed Web of Science ®Google Scholar
• Jacobson IM, Gonzalez SA, Ahmed F, A randomized trial of pegylated interferonalpha-2b plus ribavirin in the retreatment of chronic hepatitis C. Am J Gastroenterol 2005;100:2453-62
   PubMed Web of Science ®Google Scholar
• Marrache F, Consigny Y, Ripault MP, Safety and efficacy of peginterferon plus ribavirin in patients with chronic hepatitis C and bridging fibrosis or cirrhosis. J Viral Hepat 2005;12:421-8
   PubMedGoogle Scholar
• Taliani G, Gemignani G, Ferrari C, . Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients. Gastroenterology 130; 2006: 1098-106
   Google Scholar
• Jensen DM, Morgan TR, Marcellin P, Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006;43:954-60
   PubMed Web of Science ®Google Scholar
• Everson GT, Hoefs JC, Seeff LB, Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: lessons from the HALT-C trial. Hepatology 2004;44:1675-84
   Google Scholar
• Zeuzem S, Buti M, Ferenci P, Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2004;44:97-103
   Google Scholar
• Sheman M, Yoshida EM, Deschenes M, Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. Gut 2006;55:1631-8
   PubMedGoogle Scholar
• Meyer-Wyss B, Rich P, Egger HP, Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 μ/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis. J Viral Hepat 2006;13:457-65
   PubMedGoogle Scholar
• Berg C, Goncales FL, Bernstein DE, Re-treatment of chronic hepatitis C patients after relapse: efficacy of peginterferon-alpha-2a (40 kDa) and ribavirin. J Viral Hepat 2006;13:435-40
   PubMed Web of Science ®Google Scholar
• Jacobson IM, Brown RS Jr, Freilich B, Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 2007;46:971-81
   PubMed Web of Science ®Google Scholar
• Silva M, Poo J, Wagner F, A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). J Hepatol 2006;45:204-13
   PubMed Web of Science ®Google Scholar
• Sporea I, Danila M, Sirli R, Comparative study concerning the efficacy of Peg-IFN alpha-2a versus Peg-IFN alpha-2b on the early virological response (EVR) in patients with chronic viral C hepatitis. J Gastrointest Liver Dis 2006;15:125-30
   PubMedGoogle Scholar
• Di Bisceglie AM, Ghalib RH, Hamzeh FM, Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. J Viral Hepat 2007;14:721-9
   PubMed Web of Science ®Google Scholar
• Escudero A, Rodriguez F, Serra MA, Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective. non-randomized study J Gastroenterol Hepatol 2008;23:861-6
   PubMedGoogle Scholar
• Chou R, Carson S, Chan BKS. Pegylated interferons for chronic hepatitis C virus infection: an indirect analysis of randomized trials. J Viral Hepat 2008;15:551-70
   PubMedGoogle Scholar
• McHutchison J, Sulkowski M. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C. J Viral Hepat 2008;15:475-81
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Lawitz EJ, Shiffman ML, Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361:580-93
   PubMed Web of Science ®Google Scholar
• Ascione A, De Luca M, Tartaglione MT, Reginterferon alpha-2a plus ribavirin versus peginterferon alpha-2b plus ribavirin in naïve patients with chronic hepatitis C virus infection: results of a prospective randomised trial [abstract]. J Hepatol 2008;48:S370
   Google Scholar
• Rumi M, Aghemo A, Prati GM, Randomized study comparing peginterferon-alfa 2a plus ribavirin and peginterferon alfa-2b plus ribavirin in naïve patients with chronic hepatitis C: final results of the Milan safety tolerability (MIST) study [abstract]. Hepatology 2008;48:404A
   Google Scholar
• Hassanein TI, Ye X, Blumentals WA, Clinical and persistency outcomes in hepatitis C patients treated with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin [abstract]. J Hepatol 2008;48:S295-6
   Google Scholar
• Craxi A, Piccinino F, Alberti A, Predictors of SVR in naïve HCV G1 patients in real life practice: the PROBE [abstract]. J Hepatol 2008;48:S291
   Web of Science ®Google Scholar
• Witthoeft T, Hueppe D, John C, Efficacy and safety of peginterferon alfa-2a or -2b plus ribavirin in the routine daily treatment of chronic hepatitis C patients in Germany: the PRACTICE study [abstract]. J Hepatol 2008;48:S315
   Google Scholar
• Venugopal K, Mollison L, Miczkova S, Comparing outcomes in patients with treatment naïve chronic hepatitis C treated with 2 types of pegylated interferon, when matched for age, BMI, genotype and fibrosis scores [abstract]. J Hepatol 2008;48:S314
   Google Scholar
• Laguno M, Cifuentes C, Murillas J, Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin. to treat chronic hepatitis C in human immunodeficiency virus patients Hepatology 2009;49:22-31
   PubMed Web of Science ®Google Scholar
• Berenguer J, Gonzalez-Garcia J, Lopez-Aldeguer J, Pegylated interferon alpha2a plus ribavirin versus pegylated interferon alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. J Antimicrob Chemother 2009;63:1256-63
   PubMed Web of Science ®Google Scholar
• Vispo E, Tuma P, Medrano J, Differences in antiviral activity and tolerability between pegylated interferon alpha-2a and –2b in HIV infected patients with chronic hepatitis C [abstract]. J Hepatol 2009;50:S238-9
   Google Scholar
• Jensen DM, Marcellin P. Rationale and design of the REPEAT study: a phase III, randomized, clinical trial of peginterferon alfa-2a (40 kDa) plus ribavirin in non-responders to peginterferon alfa-2b (12 kDa) plus ribavirin. Eur J Gastroenterol Hepatol 2005;17:899-904
   PubMedGoogle Scholar
• Jensen DM, Marcellin P, Freilich B, Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b. A randomized trial. Ann Intern Med 2009;150:528-40
   PubMed Web of Science ®Google Scholar
• Poynard T, Colombo M, Bruix J, Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ ribavirin therapy. Gastroenterology 2009;136:1618-28
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Everson GT, Gordon SC, Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360:1827-38
   PubMed Web of Science ®Google Scholar
• Dusheiko GM, Hezode C, Pol S, Treatment of chronic hepatitis C with telaprevir (TVR) in combination with peginterferon-alfa-2a with or without ribavirin: further interim analysis results of the PROVE 2 study [abstract]. J Hepatol 2008;48:S26
   Web of Science ®Google Scholar
• Manns M, Muir A, Adda N, Telaprevir in hepatitis C genotype-1-infected patients with prior non-response, viral breakthrough or relapse to peginterferon alfa-2a/b and ribavirin therapy: SVR results of the PROVE 3 study [abstract]. J Hepatol 2009;50:S379
   Google Scholar
• Nelson D, Pockros PJ, Godofsky E, High end-of-treatment response (84%) after 4 weeks of R1626, peginterferon alfa-2a (40KD) and ribavirin followed by a further 44 weeks of peginterferon alfa-2a and ribavirin [abstract]. J Hepatol 2008;48:S371
   PubMed Web of Science ®Google Scholar
• Kwo P, Lawits E, McCone J, HCV SPRINT-1 final results: SVR 24 from a phase 2 study of boceprevir plus Pegintron (peginterferon alfa-2b)/ribavirin in treatment-naïve subjects with genotype-1 chronic hepatitis C [abstract]. J Hepatol 2009;50:S4
   PubMed Web of Science ®Google Scholar
• Manns M, Reesink H, Moreno C, OPERA-1 trial: interim analysis of safety and antiviral activity of TMC435 in treatment-naïve genotype 1 HCV patients [abstract]. J Hepatol 2009;50:S7
   PubMedGoogle Scholar
• Kukolj G, Benhamou Y, Manns MP, BI201335, a potent HCV NS3 protease inhibitor, in treatment-naïve and -experienced chronic HCV genotype-1 infection: genotypic and phenotypic analysis of the NS3 protease domain [abstract]. J Hepatol 2009;50:S347
   Google Scholar
• Manns MP, Gane E, Rodriguez-Torres M, MK-7009 significantly improves rapid viral response (RVR) in combination with pegylated interferon alfa-2a and ribavirin in patients with chronic hepatitis C (CHC) genotype 1 infection [abstract]. J Hepatol 2009;50:S384
   Google Scholar
• Shiffman M, Ahmed A, Jacobson I, Phase 2 randomized, double-blind, placebo-controlled study of nitazoxanide with peginterferon alfa-2a and ribavirin in nonresponders (NR) with chronic HCV genotype 1: week 28 interim analysis [abstract]. J Hepatol 2009;50:S385-6
   Google Scholar